A share price of Xeris Biopharma Holdings Inc [XERS] is currently trading at $3.41, up 3.65%. In order to assess the stock’s recent performance, you can check whether its short-term value is rising or falling.
From an analyst’s perspective:
Xeris Biopharma Holdings Inc [NASDAQ: XERS] stock has seen the most recent analyst activity on November 11, 2024, when Piper Sandler downgraded its rating to a Neutral but kept the price target unchanged to $3 for it. Previously, Oppenheimer started tracking the stock with Outperform rating on March 28, 2024, and set its price target to $5. On August 28, 2023, Craig Hallum initiated with a Buy rating and assigned a price target of $4.50 on the stock. Jefferies started tracking the stock assigning a Buy rating and suggested a price target of $4 on October 21, 2022. Craig Hallum initiated its recommendation with a Buy and recommended $6.50 as its price target on April 28, 2022. SVB Leerink started tracking with a Outperform rating for this stock on November 17, 2021, and assigned it a price target of $6. In a note dated October 29, 2021, H.C. Wainwright initiated an Buy rating and provided a target price of $4 on this stock.
Xeris Biopharma Holdings Inc experienced fluctuations in its stock price throughout the past year between $1.69 and $3.87. Currently, Wall Street analysts expect the stock to reach $5.8 within the next 12 months. Xeris Biopharma Holdings Inc [NASDAQ: XERS] shares were valued at $3.41 at the most recent close of the market. An investor can expect a potential return of 70.09% based on the average XERS price forecast.
Analyzing the XERS fundamentals
Trailing Twelve Months sales for Xeris Biopharma Holdings Inc [NASDAQ:XERS] were 187.36M which represents 12.31% growth. Gross Profit Margin for this corporation currently stands at 0.77% with Operating Profit Margin at -0.24%, Pretax Profit Margin comes in at -0.35%, and Net Profit Margin reading is -0.34%. To continue investigating profitability, this company’s Return on Assets is posted at -0.2, Equity is 3.97 and Total Capital is -0.2. An extended analysis of the company’s primary financial structure reveals a debt-to-equity ratio of-9.57.
Before buying any particular stock, readers tend to pay close attention to the indicators that support and create resistance. The company’s stock is currently sitting at 3.29 points at the first support level, and at 3.17 for the second support level. However, for the 1st resistance point, the stock is sitting at 3.48, and for the 2nd resistance point, it is at 3.55.
Ratios To Look Out For
To put it in perspective, the Current Ratio for Xeris Biopharma Holdings Inc [NASDAQ:XERS] is 1.79. In addition, the Quick Ratio stands at 1.29 and the Cash Ratio stands at 0.65. Considering the valuation of this stock, the price to sales ratio is 2.71.
Transactions by insiders
Recent insider trading involved Schmid John P., Director, that happened on Aug 12 ’24 when 4515.0 shares were purchased. Director, Schmid John P. completed a deal on Aug 09 ’24 to buy 4285.0 shares. Meanwhile, Director Schmid John P. bought 5400.0 shares on May 10 ’24.
